Key Takeaways Regarding Biomarker Testing for mNSCLC
Closing thoughts from a panel of NSCLC experts, with an emphasis on improving access to and utilization of biomarker testing for patients with the disease.
Insights into Third-Line Treatment Selection for Patients with EGFR Exon 20-mutated mNSCLC
Experts consider how they might approach third-line treatment selection for patients with EGFR exon 20-mutated mNSCLC who experience disease progression on amivantamab or other second-line therapies.
Patient Case 2: Second-line Treatment Selection and Adverse Event Management
Dr Velázquez Mañana revisits the second patient case and details the use of second-line amivantamab for the patient’s disease progression, and the panel confers about adverse event management strategies for patients taking this regimen.
Data-Informed Insights on Second-line Treatment Selection for EGFR Exon 20-mutated mNSCLC
Dr Porter presents recent conference data on a matching-adjusted indirect comparison of amivantamab and mobocertinib for treatment of EGFR exon 20-mutated mNSCLC, and panelists weigh in on factors influencing selection between the two regimens.
Safety and Efficacy Data for Mobocertinib in Patients with mNSCLC
Dr Jason Porter presents safety and efficacy data from a Phase 1/2 study on mobocertinib in patients with mNSCLC.
CHRYSALIS: Study Design and Key Results for Amivantamab in mNSCLC
A brief overview of study design, patient demographics, data from the phase 1 CHRYSALIS trial, which assessed the safety and efficacy of amivantamab in patients with EGFR exon 20-mutated, advanced or metastatic NSCLC.
Managing Disease Progression in Patients with EGFR-mutated mNSCLC
Continuing the discussion of the presented case of EGFR exon 20-mutant mNSCLC, Dr Velázquez Mañana outlines how the patient experienced disease progression on first-line treatment, after which the panel shares clinical insights and best practices on how they might approach subsequent treatment selection in this scenario.
Patient Case 2: mNSCLC with an EGFR Exon 20 Insertion
Dr Ana Velázquez Mañana introduces a second patient case, a 59-year-old Black man diagnosed with mNSCLC and an EGFR exon 20 insertion, and outlines first-line treatment selection for the patient.
Overcoming Disparities in Biomarker Testing Use for mNSCLC
Expert panelists react to the presented data on racial and socioeconomic disparities in biomarker testing for patients with mNSCLC, and align on ways to address and overcome these disparities.
An Introduction to Three Real-World Analyses of Biomarker Testing Patterns in mNSCLC
Dr Jason Porter introduces three recent retrospective observational studies on use of biomarker testing in mNSCLC, which identified racial and socioeconomic disparities in testing patterns.
Challenges of Using Biomarker Testing in mNSCLC
Panelists continue their dialogue on common challenges and barriers to use of biomarker testing in NSCLC, and share potential strategies to optimize use of testing.
A Molecular Pathologist’s Insight into Institutional Best Practices for NSCLC Biomarker Testing
Dr Vail shares insight into his ideal institutional approach to biomarker testing for NSCLC, emphasizing the need for local molecular pathology expertise and available in-house biomarker panels.
Patient Case 1: A 71-year-old Woman with Newly Diagnosed mNSCLC
Eric Vail, MD introduces a patient case, a 71-year-old Asian woman newly diagnosed with mNSCLC, followed by a focused discussion on how the panel would have approached biomarker testing and treatment initiation for the patient.
Clinical Experience with Coordinating Biomarker Testing for Patients with mNSCLC
The panel discusses challenges that clinicians may experience when ordering biomarker testing for patients with mNSCLC, including insurance coverage barriers, timing of testing, insufficient biopsy samples, and inconclusive test results.
Available Biomarker Testing Modalities for Patients with mNSCLC
Panelists discuss available biomarker testing methodologies for metastatic NSCLC (mNSCLC), sharing how they optimize molecular profiling in their practices and whether they typically use commercial or in-house tests.
Analyzing the Relationship Between Biomarkers, Testing Rates, and Clinical Characteristics in Non-Small Cell Lung Cancer
Jason Porter, MD, and fellow panelists discuss how expression of NSCLC biomarkers and biomarker testing rates may vary by patients’ clinical characteristics, including tumor histology, stage, race, and sex.
An Introduction to Biomarker Testing in Non-Small Cell Lung Cancer
Expert panelists are introduced and review common biomarkers in non-small cell lung cancer (NSCLC), followed by a focused discussion on EGFR mutations.
2 Clarke Drive Cranbury, NJ 08512